Literature DB >> 3927950

Nutrition and cancer: physiological interrelationships.

J van Eys.   

Abstract

There are many tumors that have paraneoplastic syndromes. Furthermore, location of certain tumors can result in very specific effects on the host, especially tumors in the hypothalamus, the intestinal tract, or the liver. Finally, tumors of the immune system can have significant distant consequences. However, from direct experimental evidence, from model systems, and from the utilization of nutritional manipulation in the treatment of cancer, the data suggest very strongly that there is no unique cancer malnutrition. Early diagnosed cancer does not show malnutrition as a presenting symptom. Furthermore, all metabolic disturbances can be explained on the basis of the metabolic differences of tumor cells and normal cells and are very frequently proportional to the bulk of the tumor. The cachexia that is associated with malignancies is more likely cachexia in cancer patients than it is a specific cancer cachexia, unless the tumor burden is very large. This point was clearly made in a short review of the causes of cachexia in nearly 1500 cancer patients in Russia (145). Brennan also feels that most cases of malnutrition are uncomplicated starvation, and cancer cachexia has many features seen in major injury or sepsis (16). This distinction has great implications in the management of cancer patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3927950     DOI: 10.1146/annurev.nu.05.070185.002251

Source DB:  PubMed          Journal:  Annu Rev Nutr        ISSN: 0199-9885            Impact factor:   11.848


  15 in total

Review 1.  Relevance of glutamine metabolism to tumor cell growth.

Authors:  M A Medina; F Sánchez-Jiménez; J Márquez; A Rodríguez Quesada; I Núñez de Castro
Journal:  Mol Cell Biochem       Date:  1992-07-06       Impact factor: 3.396

2.  Enteral nutrition after bone marrow transplantation.

Authors:  A Papadopoulou; A MacDonald; M D Williams; P J Darbyshire; I W Booth
Journal:  Arch Dis Child       Date:  1997-08       Impact factor: 3.791

Review 3.  Specificity of the suppression of metastatic phenotype by tyrosine and phenylalanine restriction.

Authors:  C A Elstad; G G Meadows; R M Abdallah
Journal:  Clin Exp Metastasis       Date:  1990 Sep-Oct       Impact factor: 5.150

Review 4.  Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase.

Authors:  S P Mathupala; A Rempel; P L Pedersen
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

5.  Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia.

Authors:  K J Tracey; S Morgello; B Koplin; T J Fahey; J Fox; A Aledo; K R Manogue; A Cerami
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

Review 6.  The metabolic environment of cancer.

Authors:  J M Argilés; J Azcón-Bieto
Journal:  Mol Cell Biochem       Date:  1988-05       Impact factor: 3.396

7.  Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts.

Authors:  Cheng-Jeng Tai; Hang Wang; Chien-Kai Wang; Chen-Jei Tai; Ming-Te Huang; Chih-Hsiung Wu; Ray-Jade Chen; Li-Jen Kuo; Po-Lei Wei; Yu-Jia Chang; Chun-Chao Chang; Hung-Yi Chiou; Chang-Jer Wu
Journal:  Clin Exp Med       Date:  2016-03-19       Impact factor: 3.984

8.  Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer.

Authors:  Suresh Kumar; Hiromitsu Kishimoto; Hui Lin Chua; Sunil Badve; Kathy D Miller; Robert M Bigsby; Harikrishna Nakshatri
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

9.  Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.

Authors:  Swarnali Acharyya; Katherine J Ladner; Lori L Nelsen; Jeffrey Damrauer; Peter J Reiser; Steven Swoap; Denis C Guttridge
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Effect of combined administration of a synthetic low-toxicity lipid A derivative, DT-5461a, and indomethacin in various experimental tumor models of colon 26 carcinoma in mice.

Authors:  T Jimbo; T Akimoto; A Tohgo
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.